Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.

Trial Details

NCT ID

NCT07604571

Phase

PHASE1

Sponsor

Novartis Pharmaceuticals

Status

RECRUITING

Cancer Type

ER/PR Positive (Hormone Receptor Positive) Breast Cancer

Interventions

IEV407
Fulvestrant
Letrozole

Locations (sample)

Dallas, Texas, United States|32.78306,-96.80667
Hirakata, Osaka, Japan|34.81352,135.64914
Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

Age ≥ 18 years old
Patients with one of the following indications:
Dose escalation (IEV407 single agent and in combination with fulvestrant or letrozole):
HR+/HER2- aBC with disease progression on or following, or have been intolerant to, at least one line of endocrine-based therapy in combination wit…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →